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Abstract
Background Consolidated memories can undergo enduring modification through retrieval-dependent treatments that modulate
reconsolidation. This represents a potentially transformative strategy for weakening or overwriting the maladaptive memories
that underlie substance use and anxiety/trauma-related disorders. However, modulation of naturalistic maladaptive memories
may be limited by ‘boundary conditions’ imposed on the reconsolidation process by the nature of these memories.
Methods We conducted a systematic review and meta-analyses of behavioural and pharmacological studies examining retrieval-
dependent modulation of reward- and threat-related memories in (sub) clinical substance use and anxiety/trauma, respectively.
Results Of 4938 publications assessed for eligibility, 8 studies of substance use and 10 of anxiety (phobia)- and trauma-related
symptoms were included in the meta-analyses. Overall, the findings were in the predicted direction, with most studies favouring
the ‘retrieval + treatment’ condition. However, the magnitude of effects was dependent upon the nature of treatment, with
pharmacological interventions showing a medium-sized effect (g = 0.59, p = 0.03) and behavioural treatments, a relatively small
effect (g = 0.32, p = 0.10) in studies of phobia/trauma. Among studies of substance use, post-retrieval behavioural interventions
yielded a larger effect (g = 0.60, p < 0.001) relative to pharmacological treatments (g = − 0.03, p = 0.91), with treatment type
being a statistically significant moderator (χ2(1) = 4.20, p = 0.04).
Conclusion Modification of naturalistic maladaptive memories during reconsolidation appears to be a viable treatment strategy
for substance use and phobias/trauma disorders. However, high levels of heterogeneity and methodological variation limit the
strength of conclusions that can be drawn from the reviewed studies at this stage.
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Introduction
Phobia, traumatic stress and substance use disorders
as disorders of memory
Threat-related disorders (phobia and traumatic stress) and sub-
stance use disorders (SUDs) can be conceptualised as disor-
ders of maladaptive associative memory (Fanselow and
Sterlace 2014; McCarthy et al. 2011; Hyman 2005). The pro-
cesses underlying the formation and maintenance of these
maladaptive memories are thus highly relevant to the treat-
ment of these disorders. The failure of existing therapies to
attenuate the emotional/motivational influence of maladaptive
memories is one reason why treated individuals are vulnerable
to relapse, even after prolonged remission/abstinence
(Shaham et al. 2003; Shalev et al. 2002; Staiger and White
1991).
Recent advances in neuroscience have set the stage for the
development of a new generation of treatments that focus on
reducing the symptom-maintaining influence of maladaptive
memories and the attainment of lasting protection against re-
lapse (Kamboj and Das 2017). The current review focuses on
a specific retrieval-dependent form of memory plasticity—
reconsolidation—that can potentially be manipulated to ame-
liorate anxiety/trauma and SUD symptoms by targeting the
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naturalistic maladaptive memories that underlie them. The
term ‘naturalistic memories’ refers to memories that are natu-
rally (rather than experimentally) acquired. The learning his-
tory of naturally acquired maladaptive memories is usually
unknown (except perhaps, in the case of recent, single-
incident traumas underlying post-traumatic stress disorder,
PTSD), although it is assumed that in general, these memories
are formed through multiple, intermittent reinforcements
(Pavlovian and instrumental) in a variety of contexts and over
a prolonged period. This is generally radically different from
the situation for experimentally acquired memories, upon
which, the vast majority of animal and human reconsolidation
research has been conducted.
Memory reconsolidation
Historically, consolidated memories in long-term storage were
thought to be stable and resistant to modification (cf.
McGaugh 2000). However, over the past two decades, numer-
ous studies have convincingly demonstrated that under certain
retrieval conditions, even apparently long-established, puta-
tively cortically distributed memories can enter a transient
labile state during which they are susceptible to modification
before being restored in long-term memory (e.g. Graff et al.
2014; Robinson and Franklin 2010; Suzuki et al. 2004). This
process is commonly referred to as reconsolidation and con-
sists of two temporally and pharmacologically dissociable
stages: (a) retrieval-induced reactivation or destabilisation of
a previously consolidated memory and (b) its restabilisation
in an updated or strengthened form (Lee 2009). Although
reactivation engenders a period of memory instability which
is required for normative memory strengthening and updating,
stored representations are also susceptible to pronounced dis-
ruption during reconsolidation using pharmacological agents
and behavioural procedures.
Weakening maladaptive memories: disruption
of restabilisation with pharmacological agents
The restabilisation phase of the reconsolidation cycle is protein
synthesis-dependent. Drugs that directly and indirectly interfere
with protein synthesis can therefore disrupt this phase. The most
potent drugs (e.g. anisomycin or cycloheximide) interfere direct-
ly with cellular translational machinery and macromolecule bio-
synthesis. However, these drugs are toxic and not safe for human
use. As such, an alternative approach has involved indirect inhi-
bition of protein synthesis through, for example, upstream neu-
rotransmitter blockade. While a number of studies have exam-
ined such indirect modulation via diverse drugs (e.g. glucocorti-
coid, glutamatergic and GABAergic compounds), there are rela-
tively few human studies using these drug classes (cf. Das et al.
2015a, 2018a; Meir Drexler et al. 2015, 2016; Rodríguez et al.
2013;Wood et al. 2015). By contrast, theβ-blocker, propranolol,
has proven to be a particularly popular tool for probing
reconsolidation in humans, especially in laboratory studies of fear
conditioning (e.g. Bos et al. 2014; Kindt et al. 2009; Schroyens et
al. 2017; Sevenster et al. 2012, 2013, 2014; Soeter and Kindt,
2010, 2011, 2012a, b, 2015a, b). Other studies have extended
these experimental findings with propranolol to clinical popula-
tions, showing enduring retrieval-dependent reductions in trauma
symptoms in people with PTSD (Brunet et al. 2018) and fear in
spider phobics (Soeter and Kindt 2015a), as well as drug craving
among addicted individuals (e.g. Xue et al. 2017).
Rewriting maladaptive memories using behavioural
techniques
An alternative approach involves disrupting memory expres-
sion via reconsolidation interference using purely behavioural
strategies (e.g. Monfils et al. 2009). By targeting memory
networks that are causally implicated in symptom expression,
this approach aims to overcome the limitations of traditional
inhibitory training (extinction) strategies. In particular, initial-
ly successful extinction is often followed by the ‘return of
fear’—or in the case of substance use disorders, the recurrence
of craving and drug seeking—following re-exposure to un-
conditioned stimuli (USs; reinstatement), the simple passage
of time (spontaneous recovery) or change in context (renew-
al). This strongly suggests that maladaptive associative mem-
ories persist following typical extinction-based therapies and
might contribute to relapse (Bouton 2002; Conklin and
Tiffany 2002). Reconsolidation-based behavioural (and phar-
macological) treatments can potentially overcome these issues
through a direct updating of reactivated memory networks.
In support of this idea, extinction learning after fear mem-
ory retrieval (so-called ‘retrieval-extinction’) eliminates and
prevents the return of fear in rats (e.g. Monfils et al. 2009)
and humans (Johnson and Casey 2015; Schiller et al. 2010).
Similarly, relative to extinction without prior retrieval,
retrieval-extinction leads to enduring reductions in reactivity
to drug cues in rodent models of addiction (e.g. Cofresi et al.
2017; Xue et al. 2012) and in human substance users
(Germeroth et al. 2017; Xue et al. 2012; see Kredlow et al.
2016 for a recent review of post-retrieval-extinction effects),
suggesting that this procedure may be a general-purpose strat-
egy for lasting modification of maladaptive memories. Other
therapeutically applicable post-retrieval learning strategies
might also be suited to updating appetitive and threat memo-
ries in humans, although these have received less attention (cf.
Das et al. 2015b; Hon et al. 2016).
Putative boundary conditions on memory
destabilisation
Despite the therapeutic implications of reconsolidation inter-
ference hinted at above, there appear to be some inbuilt limits
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on the regular destabilisation-restabilisation of naturally ac-
quired memories. In particular, ongoing and indiscriminate
memory interference following retrieval is constrained by a
number of proposed ‘boundary conditions’ that limit
destabilisation. Of particular relevance to naturalistic mal-
adaptive memories, older and more strongly encoded associ-
ations appear to be relatively resistant to destabilisation fol-
lowing simple retrieval procedures (e.g. Alfei et al. 2015;
Milekic and Alberini 2002; Robinson and Franklin 2010;
Suzuki et al. 2004). In contrast, experimental studies showing
robust reconsolidation effects, particularly in humans, often
involve experimentally generated memories (especially con-
ditioned fear), which are often reactivated mere days after
training. These simulated maladaptive memories reflect pro-
foundly different learning intensities compared to their natu-
ralistic counterparts in phobia/trauma and SUDs. Associative
learning in these disorders involves highly salient USs at
encoding (supporting single-trial learning) or reinforcement
over many years in multiple contexts. For example, the
typical ‘pack-a-day’ smoker will experience close to 106
reinforcements (puffs on a cigarette) over 12 years of reg-
ular smoking. These distinct properties of naturalistic mem-
ories (asymptotic learning and temporal remoteness) rela-
tive to experimentally learned associations (sub-maximal
learning and recency) potentially severely limit the appli-
cation of findings from experimental conditioning studies
to the treatment of psychological disorders with
reconsolidation interference strategies.
In addition, variation in stimulus predictability at retrieval
may moderate the ability of retrieval procedures to labilise
naturalistic maladaptive memories. In particular, accumulat-
ing experimental evidence suggests that a relevant prediction
error (PE) at retrieval may be important for enabling full
destabilisation of memory networks (e.g. Alfei et al. 2015;
Exton-McGuinness et al. 2015; Kindt and van Emmerik
2016; Pedreira et al. 2004; Sevenster et al. 2013, 2014). As
an illustration, Das et al. (2015b) found that while simple
retrieval cues (followed by counterconditioning) produced in-
termediate levels of memory updating, incorporation of a PE
at retrieval appeared to result in more pronounced rewriting of
alcohol memories. More recently, Das et al. (2018a) found no
evidence of a reconsolidation-blocking effect of post-retrieval
nitrous oxide gas (a putative NMDA receptor antagonist) in
heavy drinkers, although reanalysis that took account of the
level of experienced PE (subjective surprise ratings) at retriev-
al revealed a significant reduction in craving and drinking
behaviour in the retrieval + nitrous oxide group among partic-
ipants experiencing high PE following reward omission dur-
ing retrieval. As such, extant studies in humans that demon-
strate weakening/updating of naturalistic maladaptive memo-
ries without the use of explicit PE-generating procedures dur-
ing retrieval (the majority of published studies) may reflect a
lower bound of efficacy of such interventions, due to sub-
optimal reactivation of maladaptive memory networks.
However, while evidence of the PE dependence of
destabilisation has been demonstrated in studies of experi-
mentally acquired memories in humans (e.g. Sevenster et al.
2013; see also Fernández et al. 2016), this has yet to be tested
through systematic variations in the degree of PE during
reactivation of memories with fixed and unknown learning
histories (i.e. naturalistic memories). More generally, opti-
mal retrieval parameters (e.g. the duration or number of
conditioned stimulus (CS) presentations or the use of USs
rather than CSs at retrieval; Exton-McGuinness et al. 2015;
Merlo et al. 2014) have not been thoroughly studied in
humans, leaving some uncertainty about the suitability of
the retrieval procedures used in extant studies of naturally
acquired memories.
The current review
To date, reviews and meta-analyses on reward and fear mem-
ory reconsolidation have largely focused either on non-human
animals (e.g. Das et al. 2013) or in the case of human studies,
primarily on experimentally generated memories focusing
on a single reconsolidation interference strategy (e.g.
Kredlow et al. 2016; Lonergan et al. 2013) or memory sys-
tem (Scully et al. 2017). Such analyses are critical for fur-
thering our understanding of the modulators of this funda-
mental memory process. However, a determination of the
utility of reconsolidation modulation as a therapeutic strat-
egy requires a synthesis of studies in which clinically im-
portant symptoms are targeted in appropriate populations.
To our knowledge, no comprehensive synthesis has been
conducted on the effects of reconsolidation modulation
strategies specifically directed at clinically relevant
reward- and threat-related memories in humans. As noted
above, the distinct properties of strongly encoded and re-
mote naturalistic maladaptive memories versus those
formed during experimental procedures may be extremely
important in determining the translational utility of labora-
tory findings. Moreover, it might be that differences in the
neural substrates of learning, and the distinctive learning
histories associated with appetitive memories versus
threat-related memories, render addictive and phobia/
traumatic stress disorders differentially susceptible to
reconsolidation treatments due to differences in ‘reactivation
potential’ of their underlying maladaptive memories.
However, this has yet to be formally tested. Finally, a system-
atic comparison of behavioural versus pharmacological
strategies has yet to be conducted. The current meta-analysis
therefore addresses the lack of a systematic synthesis of be-
havioural versus pharmacological reconsolidation interfer-
ence strategies applied to human substance-using and
anxious/trauma-exposed (clinical and sub-clinical) samples.
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Methods
Search strategy
PsycINFO, PubMed, Web of Science and Scopus databases
were searched on 03/10/2017 using search terms based on a
scoping search on experimental and therapeutic modulation of
reconsolidation. The search terms were as follows: (memory)
AND ((((((((reactivat*) OR destabiliz*) OR destablis*) OR
memory reconsolidation) OR reconsolidation) OR
reconsolidation-extinction) OR extinction) OR retrieval)
AND ((((((((((((((((((pharmacologic*) OR NMDA) OR N-
methyl-D-aspartate) OR adrenoceptor) OR adrenergic) OR
noradrenergic) OR beta adreno) OR adrenoreceptor) OR sym-
pathetic) OR sympathetic nervous system) OR dopamine) OR
dopaminergic) OR glucocorticoid*) OR cortisol) OR benzo-
diazepine) OR calcium channel) OR extinction) OR exposure)
AND (((((((((((avers*) OR appetit*) OR fear) OR anxiety) OR
PTSD) OR addiction) OR substance use disorder) OR sub-
stance use) OR drug use) OR drug) OR reward).
The search was limited to human studies and excluded
reviews. The international clinical trials registry platform
and clinicaltrials.gov were searched using the term
‘reconsolidation’, after which a search of the identified
authors’ current publications was conducted. The reference
lists of the following reviews were also checked for relevant
studies: Centonze et al. (2005), de Kleine et al. (2013), de
Quervain et al. (2000), Dennis and Perrotti (2015), Farach et
al. (2012), Gisquet-Verrier and Riccio (2012), Högberg et al.
(2011), Kredlow et al. (2016), Lee et al. (2017), Makkar et al.
(2012), Milton (2013), Milton and Everitt (2010), Pitman
(2011) and Schwabe et al. (2014). Authors of all included
studies were contacted regarding unpublished data.
Study inclusion criteria
Figure 1 outlines the search, screening and selection process,
in line with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA). Selection of studies
was restricted to those that examined a reconsolidation-
modulating (retrieval-dependent) pharmacological or behav-
ioural strategy targeting naturally, rather than experimentally,
acquired memories. In addition, studies were required to as-
sess symptoms relevant to substance use or anxiety/trauma
disorders reflecting effects on long-term (≥ 24 h) memory.
Participants were required to be recruited on the basis of ele-
vated anxiety, experience of trauma or problematic alcohol/
substance use. There was no requirement for a formal diagno-
sis or for participants to be seeking treatment. Studies were
required to randomise adult participants to a ‘retrieval +
(reconsolidation-interfering) treatment’ or control group (see
below) and contain n ≥ 15 per condition at randomisation
(although the final ES calculation was based on the eventual
sample, after exclusions/dropouts). The decision to include
only studies with n ≥ 15/group was based on pragmatic con-
siderations relating to the limited number of studies with sub-
stantial sample sizes. Only studies reported in English were
included. Abstracts were reviewed for eligibility by the first
author. Eighteen studies that examined pharmacological or
behavioural strategies for modifying naturalistic appetitive or
threat-related memories via reconsolidation in clinical or sub-
clinical human samples were included. Note, one study (Jobes
et al. 2015) that initially met inclusion criteria was excluded
following discussion due to the complex nature of the design,
which involved participants receiving methadone at various
times during the intervention (either pre- or post-retrieval).
This was in addition to the reconsolidation-interfering study
of medication (propranolol), making it impossible to disentan-
gle opioid from β-adrenergic treatment effects. In addition, it
should be noted that a recent study on the effects of propran-
olol on smoking memories (Xue et al. 2017) did not meet
criteria because the effects were primarily related to experi-
mentally acquired, rather than naturalistic smoking memories.
Methodological evaluation of studies
Identifying information (authors, institutions, journal details
and mention of significance of results) was obscured from in-
cluded papers before assessment of the BMethods^ section by
two (nominally blind) investigators. The tool for methodologi-
cal appraisal was a modified version of an instrument used in
our previousmeta-analysis of reconsolidation studies (Das et al.
2013). The level of inter-coder agreement was 83%, and any
discrepancies in ratings were resolved through discussion.
Data extraction
Details regarding the study protocol, including memory re-
trieval procedure, outcome measures, treatment timing (rela-
tive to retrieval), type (behavioural or pharmacological) and
dose, as well as ‘disorder’ type were extracted from the select-
ed articles.
Outcome measures
A preliminary review of the selected studies identified specific
outcomes for use in effect size (ES) calculation. These were
selected based on the regularity with which these measures
were reported across studies. We chose this approach in pref-
erence to determining ESs for published significant effects in
order to minimise bias, since some of the included studies
were not identified as clinical trials, and therefore had no
pre-determined (registered) outcomes. As such, subjective
craving, an important clinical target in SUD treatment,
reflecting conditioned responding to drug cues (i.e. the sub-
jective expression of retrieved drug-related memories) was the
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primary outcome in the current analysis of substance use stud-
ies, as it was reported in all relevant publications. Similarly,
studies of phobias consistently used the behavioural approach
test (BAT), although the nature of outcomes from this test
varied from study to study [e.g. distance between participant
and feared object (Shiban et al. 2015); subjective fear ratings
during proximal approach (Telch et al. 2017)]. Finally, of the
five trauma-related studies, the most commonly reported out-
come was PTSD symptom severity (four studies; Table 1) and
one study reported memory performance (number of recalled
trauma event details; Kredlow and Otto 2015).
Statistical approach
Effect size determination
Data required for ES determination were extracted by the first
author. Random effects models (DerSimonian and Laird
1986) were selected, and the generic inverse variance method
was used. ESs were calculated as between-groups
standardised mean differences (Hedge’s g; Higgins and
Green 2011) using the Review Manager software (version
5.3; the Cochrane collaboration, 2014) and interpreted using
the standards of Cohen (1988) and Sawilowsky (2009): ~ 0.1
= very small, ~ 0.2 = small, ~ 0.5 = medium, ~ 0.8 = large and
~ 1.2 = very large. Intermediate descriptive labels (e.g. small–
medium) were used to describe ESs, where appropriate.
ESs related to the primary 1 df comparison of interest,
namely retrieval + treatment (pharmacological or behavioural)
versus a suitable control condition. A comparison with a no
retrieval + treatment control was deemed to best represent the
specific effect of a memory-interfering/weakening treatment
via reconsolidation. Where such a group was not used, ESs
were calculated relative to a retrieval + no treatment condition.
Other control groups are also suitable for testing
reconsolidation effects. Unlike pharmacological studies, in
which drug effects are likely to be present for several hours
(i.e. during the period ofmemory lability) even if the treatment
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Psychopharmacology (2018) 235:2507–2527 2511
Table 1 Study details
Study N
Cont:Tx
%
Male
Mean
Age
Retrieval-
dependent
treatment
Control
condition
Reconsolidation
procedure
Outcome
(ES calculation)
Effects reported in
publication
(bold=result used for ES
calculation)
Phobia/trauma studies
Björkstrand
et al. (2016)
Specific
(spider)
phobia
20:20 26.7% 26.20 Retrieval-extinction RETRIEVAL+
6hr
+ Tx*
Retrieval (12s)➔
10-min➔
Exposure
Approach
behaviour
(BAT)
↓ in BOLD response to
familiar and novel cue
(1 day)
↑ in approach behaviour
(1 day)
↑ Proportion of spider
versus neutral pictures
views (6 months)
↓ in BOLD response to cue
in right amygdala (6
months)
No Δ BOLD response to
cue in left amygdala
(6 months)
Brunet et al.
(2018)
30:30 41.7% 39.4 Propranolol RETRIEVAL+
NTx
0.67 mg/kg propranolol
(SA)➔
120 min; session 1)
➔1.0 mg/kg
propranolol (LA;
concurrently
administered after
session 1)➔ 90
minutes➔ Retrieval
(10-20 min)
Symptom
severity
(CAPS)
↓ CAPS, PCL-S (6 weeks;
6 months)
Kredlow &
Otto (2015)
Indirect
witnesses of
a terrorist
act
22:23 20.2% 19.30 Negative story -
interference
RETRIEVAL +
NTx
Retrieval (4-min)➔
Negative story
# details for
traumatic
event
↓ number of details for
event (1 week)
Maples-Kel-
ler et al
(2017)
Specific
(flying)
phobia
30:27 21.1% 42.11 Retrieval-extinction
(VRET)
NRETRIVAL +
Tx
Retrieval (15s)➔
10-min➔
VRET
Fear (FFI) No Δ FFI, QAF
(posttreatment; 3
months; 6 months)
No Δ FFI, QAF (12
months)
↑HR (3 month)
↓SCR (3 month)
Shiban et al
(2015)
Specific
(spider)
phobia
15:13 10.0% 31.14 Retrieval-extinction
(VRET)
NRETRIEVAL
+Tx
Retrieval (5s)➔ 10-min
➔
In vivo and VRET
Approach
behaviour
(BAT)
No Δ in approach
behaviour during BAT
(1 day)
No Δ fear ratings during
spontaneous recovery
(1 day)
No Δ in SCR (1 day)
No Δ in-vivo fear ratings
(1 week)
No Δ self-reported
avoidance or FSQ (6
months)
Soeter &
Kindt
(2015a)
Specific
(spider)
phobia
15:15 9.0% 21.60 Propranolol NRETRIEVAL
+Tx
Retrieval (2-min)➔
40mg propranolol
Approach
behaviour
(BAT)
No Δ in numerical fear
scale (4 days)
↑ in approach behaviour
during BAT (11 days)
No Δ in SPQ (11 days)
↑ in approach behaviour
during BAT (3 months)
No Δ in self-reported fear
(3 months)
↑ in approach behaviour
during BAT (1 year)
↓ in numerical fear scale
(1 year)
Surís et al
(2013)
24:27 100% 43.02 Rapamycin RETRIEVAL+
NTx
15 mg rapamycin
(‘sirolimus’)➔
↓ CAPS in post-Vietnam
subgroup (1 month)
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Table 1 (continued)
Study N
Cont:Tx
%
Male
Mean
Age
Retrieval-
dependent
treatment
Control
condition
Reconsolidation
procedure
Outcome
(ES calculation)
Effects reported in
publication
(bold=result used for ES
calculation)
Patients
(Vietnam
and
post-Vietna-
m era
veterans)
with PTSD
retrieval(30-75 min;
average:45-min)
Symptom
severity
(CAPS)
No Δ CAPS, PCL,
QIDS-SR (1 month)
No Δ CAPS, PCL,
QIDS-SR (3 months)
Telch et al
(2017)
Specific
(spider/-
snake)
phobia
17:15 12.5% 21.31 Retrieval-extinction Tx+
RETIEVA-
L**
Retrieval (10s)➔ 30
minutes➔
In vivo exposure (3-min
x6)
Peak fear during
behavioural
approach
(BAT)
No Δ peak fear during BAT
(1 day)
No Δ expected fear during
BAT (1 day)
↓ in peak fear during
BAT renewal test (1
month)
No Δ expected fear during
BAT (1 month)
No Δ FSQ (1 month)
Wood et al
(2015;
Study 2)
Patients
(civilians
and
veterans)
with PTSD
15:13 71.43% 45.75 Mifepristone NRETRIEVAL+
Tx
1800mg mifepristone➔
90-min➔ retrieval
(duration not
specified)
Symptom
severity (IES)
No Δ IES-R, Physiological
‘PTSD probability
score’, HR, SCR,
F-EMG, C-EMG (1
week)
Wood et al
(2015;
Study 3)/
Patients
(civilians)
with PTSD
15:16 45.2% 38.50 D-Cycloserine &
Mifepristone
RETRIEVAL+
NTx
100 mg D-Cycloserine
➔ 240-min➔
1800mg mifepristone
➔ 90-min➔
retrieval (duration not
specified)
Symptom
severity (IES)
No Δ IES-R, Physiological
‘PTSD probability
score’, HR, SCR,
F-EMG, C-EMG (1
week)
Substance Use
Das et al
(2015a)
Dependent
current
smokers
20:19 50.0% 28.39 Memantine NRETRIEVAL+
Tx
10 mg memantine➔
210-min➔
retrieval (5-min)
Craving (QSU) No Δ craving (1 week)
No Δ cue-induced BP;
SCR; HRV (1 week )
No Δ smoking-related
attentional bias (1 week)
No Δ relapse latency (3
month)
No Δ nicotine dependence
(3 month)
Das et al
(2015b)
Nondepend-
ent current
hazardous
drinkers
19:20 50.0% 22.33 Counter-conditioning NRETRIEVAL+
Tx
Retrieval
(5-min)➔10-min➔
Counterconditioning
Craving (ACQ) ↓ craving (expectancy;
1 week)
↓ alcohol attentional bias
(1 week)
↓ Cue liking (1 week)
No Δ in self-reported
drinking (1 week)
Das et al
(2018a)
20:21 66% 27.25 Nitrous Oxide NRETRIEVAL+
Tx
Retrieval (5-min)➔
10-min➔ Nitrous
Oxide (30-min)
Craving (ACQ) No Δ craving (10 days)
No Δ drinking behaviour,
cue liking or
cue-induced urge to
drink (10 days)
NB following post-hoc
group reassignment
based on level of
prediction error at
retrieval (high and low
self-rated surprise
during retrieval; 10
days)
↓ craving, drinking
behaviour; cue-induced
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Table 1 (continued)
Study N
Cont:Tx
%
Male
Mean
Age
Retrieval-
dependent
treatment
Control
condition
Reconsolidation
procedure
Outcome
(ES calculation)
Effects reported in
publication
(bold=result used for ES
calculation)
urge to drink in high PE
- N2O group (10 days)
No Δ cue liking in high PE
- N2O group (10 days)
Germeroth
et al (2017)
Dependent
current
smokers
39:34 64.2% 47.50 Retrieval-extinction NRETRIEVAL+
Tx
Retrieval
(5-min)➔10-min➔
Cue exposure
Craving (QSU) ↓ # cigarettes/day (2
weeks)
No Δ craving for novel and
familiar cues (2 weeks)
No Δ CO level (2 weeks)
↓ craving for novel and
familiar cues (1month)
↓ # cigarettes/day (1
month)
↓ expired CO level (1
month)
No Δ cotinine (1 month)
No Δ cue-induced BP; HR
(1 month)
Hon et al
(2016)
Nondepend-
ent current
hazardous
drinkers
16:16 61.7% 27.00 Cognitive reappraisal NRETRIEVAL+
Tx
Retrieval (5-min)➔
10-min➔
Reappraisal
Craving (ACQ) ↓ craving
(purposefulness; 1
week)
↓ verbal fluency for +ve
alcohol words (1 week)
No Δ drinking (1 week)
No Δ attentional bias (1
week)
Pachas et al
(2015)
Dependent
current
smokers
31:23 73.0% 42.05 Propranolol
(0.67mg/kg)
RETRIEVAL+
NTx
0.67 mg/kg propranolol
(SA)➔
90 min➔1.0 mg/kg
propranolol (LA)➔
retrieval (duration not
specified)
Craving (VAS) No Δ craving (1 week)
No Δ cue
(smoking-script)--
induced HR, SCR,
EMG (1 week)
Saladin et al
(2013)
Dependent
current
cocaine
users
24:26 66.0% 39.95 Propranolol (40mg
SA)
RETRIEVAL+
NTx
Retrieval (20-min)➔
40 mg (SA) propranolol
Craving (CDMS) ↓ in craving, systolic and
diastolic BP (1 day)
No Δ in HR (1 day)
No Δ cue-induced
craving, HR, or BP (1
week)
Xue et al
(2012)
Dependent,
abstinent
heroin users
22:22 100.0% 37.70 Retrieval-extinction NRETRIEVAL+
Tx
Retrieval (5-min)➔
10-min➔
Cue exposure (60 min)
Craving (VAS) ↓ in heroin craving,
Diastolic BP, Systolic
BP, HR (4 days)
No Δ in HR (4 days)
↓ in heroin craving,
Systolic BP (34 days)
No Δ in Diastolic BP
(34 days)
No Δ in HR (34 days)
↓ in heroin craving
(184 days)
↓ in Systolic BP (184 days)
No Δ in HR, Diastolic BP
(184 days)
Note for Pachas et al 2015 and Wood et al, 2015 retrieval duration details were not provided but based on references to previous script-driven retrieval
(Pitman, et al., 1987). Note on control groups: Some studies used a three group design. Only the control group used in the ES calculation is described in
the table
NRetrieval= no retrieval, Tx= treatment,NTx=no treatment, VAS=Visual analogue scale,QSU=Questionnaire on smoking Urges; ACQ=Alcohol Craving
Questionnaire, CDSM = Craving/Distress/Mood States, BAT Behavioural Approach Test, BOLD, Blood Oxygen Level Dependent (fMRI response),
IES=Impact of Events Scale, FFI= Fear of Flying inventory, PE=prediction error VRET=Virtual reality exposure therapy; SA=short acting; LA=long
acting, SCR=skin conductance response, F-EMG=frontalis EMG, C-EMG=corrugator EMG
* retrieval followed by a 6 hr delay, followed by treatment
** treatment preceded retrieval
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is administered prior to reactivation, retrieval-dependent
memory-interfering behavioural treatment effects are the-
oretically constrained if the treatment occurs before re-
trieval. As such, treatment followed by retrieval is a suitable
control condition in behavioural studies (however, see Hutton-
Bedbrook and McNally (2013) for discussion of effects that
are not consistent with a standard reconsolidation interpreta-
tion). Finally, comparison groups in which treatment is deliv-
ered after retrieval but outside of the ‘reconsolidation window’
are also suitable controls for retrieval-dependent memory ef-
fects, as destabilisation/reactivation is a time-limited process
(lasting < 6 h).
Given that reward- and threat-related disorders have
distinct multipath aetiologies and underlying learning pro-
cesses, these disorder types were evaluated separately in
meta-analyses. Alternatively, given the aetiological simi-
larity in terms of the proposed central role of classical
conditioning in specific phobias and trauma-related disor-
ders, these two classes of disorders were considered to-
gether as a single category (phobia/trauma). Further, using
sub-group analysis, we examined whether treatment type
(behavioural versus pharmacological) produced different
population ES estimates within each broad disorder type.
Finally, we examined moderation by gender ratio, partici-
pant age and score on the methodological appraisal tool
(based on the number of positively endorsed desirable
study characteristics as a proportion of the total number
of items that could be positively endorsed) across all
studies, using these as continuous variables in meta-re-
gressions. Note, although variation in retrieval parameters
(especially retrieval trial duration and time between reac-
tivation and treatment) could affect the extent to which
memories are reactivated or weakened/overwritten, insuf-
ficient variability in these parameters prevented us from
exploring these as moderators (cf. Kredlow et al. 2016).
Sub-group analyses and forest plots were derived from
RevMan. Heterogeneity across studies was assessed using the
I2 statistic and described qualitatively; thus, ~ 25% = low, ~
50% = moderate and ~ 75% = high (Higgins et al. 2003).
Sensitivity analysis was conducted when heterogeneity was rel-
atively high and involved testing the effects of sequentially re-
moving individual studies to determine which had the greatest
influential on heterogeneity. Alternative aggregate ESs are re-
ported where removal of the most influential study resulted in a
reduction of heterogeneity to moderate levels or below (i.e. I2 <
50%).
Where insufficient information was available in publications
to calculate ESs from means/SDs and these details were not
available from authors (Pachas et al. 2015; Xue et al. 2012),
estimates were obtained from figures in the relevant publica-
tions using Plot Digitizer software (Poisot 2011). Publication
bias (symmetry of funnel plots and trim and fill) was assessed
using the MAVIS package version 1.1.3 (Hamilton et al. 2017).
Terminology
‘Reactivation’ refers to the first stage of the reconsolidation pro-
cess, as well as a memory state that is highly accessible and
malleable (Gisquet-Verrier and Riccio 2012). In addition, the
term is used to describe procedures intended to achieve this
memory state. Since the terms ‘reactivated’ and ‘destabilised’
are both used to describe a labile, potentially modifiable state
of long-term memories, we do not distinguish between these
terms and use them interchangeably. ‘Retrieval’ is used here to
refer to experimental procedures that are intended to reactivate/
destabilise memories, but whichmay or may not be successful in
this regard. This term is not intended to imply recall of a discrete
memory trace (cf. Telch et al. 2017), but, rather, retrieval or
reactivation of a more complete network of reward (substance
use) or threat-related (phobic/trauma-related) associations.
Results
Study and sample characteristics
After exclusions, the literature search yielded a total of 18
studies from 17 publications (n = 774). Five were studies on
specific phobias, five on trauma-related symptoms and eight
on substance use. Of the phobia/trauma studies, five examined
pre- or post-retrieval pharmacological interventions (Brunet et
al. 2018; Soeter and Kindt 2015a; Surís et al. 2013; Wood et
al. 2015; studies 2 and 3) and five examined post-retrieval
behavioural strategies (Bjorkstrand et al. 2017; Kredlow et
al. 2016; Maples-Keller et al. 2017; Shiban et al. 2015;
Telch et al. 2017). The eight substance use studies also exam-
ined either pharmacological (k = 4; Das et al. 2015a, 2018a;
Pachas et al. 2015; Saladin et al. 2013) or behavioural (k = 4;
Das et al. 2015b; Germeroth et al. 2017; Hon et al. 2016; Xue
et al. 2012) reconsolidation interference strategies.
Participant details (gender ratio; age) are presented in Table
1. There was a considerable variation between studies in terms
of gender ratio of participants. Among substance use studies,
gender was generally balanced or there was a higher propor-
tion of men, in line with the gender prevalence of SUD in
epidemiological studies (Seedat et al. 2009). Xue et al.
(2012) was an exception as it only included male participants
(detoxified heroin users). In contrast, studies of phobia/trauma
were generally skewed towards a higher representation of
women, again, in line with epidemiological evidence
(McLean et al. 2011). An exception was the study by Surís
et al. (2013), which only recruited men (combat veterans).
Participant age varied widely across studies, although the
mean age of participants was not statistically different (p =
0.80) between phobia/trauma studies (M = 32.83, SD =
10.12) and substance use studies (M = 34.02, SD = 8.93).
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General study methodologies
Key design features of studies and the presence/absence
of specific desirable methodological study features are
outlined in Tables 1 and 2. Table 2 shows that studies
generally contained many desirable methodological fea-
tures. The most common methodological limitations
across studies were a lack of comprehensive experimental
conditions that controlled for the effects of simple retriev-
al or treatment alone. In addition, a lack of experimenter/
assessor blinding was a virtually universal limitation of
the behavioural studies, but uncommon in pharmacologi-
cal studies.
Retrieval procedures
Most studies used in vivo exposure to CSs (e.g. powder
resembling crack cocaine; a live spider), other visual rep-
resentations of the CS (e.g. video of cocaine use; a series
of pictures of spiders) or both to reactivate memories. All
trauma-related studies encouraged autobiographical recall
of the traumatic incident(s) to reactivate trauma memory.
Other studies also incorporated instructions to recall
specific relevant autobiographical episodes evoked by the
CSs (e.g. Das et al. 2015a, 2015b, 2018a; Hon et al. 2016;
Pachas et al. 2015; Telch et al. 2017), and five studies
included an obvious prediction error procedure at retrieval
(Das et al. 2015a, b, 2018a; Hon et al. 2016; Soeter and
Kindt 2015a). The latter involved some form of expecta-
tion violation (e.g. generating an expectation that the
participant will experience the US, and then violating
this expectation; Das et al. 2018b).
As outlined in Tables 1 and 2, most studies provided
some details about the duration of the retrieval proce-
dure. The modal duration in substance use studies was
5 min (used in six of the seven studies specifying re-
trieval duration); one study used a longer retrieval pro-
cedure (2 × 10 min; Saladin et al. 2013). Eight of the 10
phobia/trauma studies specified the duration of the re-
trieval procedures, which varied more than the substance
use studies. All phobia studies used ≤ 2-min retrievals,
with most studies clustered in the 5–15-s range. The
three trauma-related studies that specified retrieval dura-
tion used 4, 10–20 and 30–75 min (the relevance of the
length of the retrieval procedure is outlined in the
discussion).
Table 2 Methodological/
reporting features of studies Study name A B C D E F G H I J K L M
Brunet et al. (2018) Y Y Y Y Y Y N Y N Y Y Y Y
Das et al. (2015a) Y Y N Y Y N Y Y N/A Y Y Y Y
Das et al. (2015b) Y Y Y N Y N N Y N/A Y Y N/A Y
Das et al. (2018a) Y Y N N Y N N Y N/A Y Y Y Y
Germeroth et al. (2017) Y Y Y N Y Y N Y N/A Y Y N/A N
Hon et al. (2016) Y Y N N Y Y N Y Y Y N N/A Y
Pachas et al. (2015) Y Y N Y Y Y N Y N/A N Y Y N
Saladin et al. (2013) Y Y Y Y Y Y N Y N/A Y Y Y N
Xue et al. (2012) Y Y N N Y Y N Y N/A Y Y N/A Y
Soeter and Kindt (2015a) Y Y N N Y Y Y Y N Y Y Y N
Telch et al. (2017) Y Y Y N Y Y Y Y N/A Y Y N/A Y
Bjorkstrand et al. (2017) Y N N N Y N N N N/A Y Y N/A Y
Shiban et al. (2015) Y Y Y Y Y N N Y N/A Y Y N/A N
Maples-Keller et al. (2017) Y Y N Y Y Y N Y N Y Y N/A Y
Kredlow and Otto (2015) Y N Y Y Y Y N Y Y Y Y N/A N
Surís et al. (2013) Y Y N Y Y Y N Y N Y Y N Y
Wood et al. (2015; study 2) Y Y N Y Y Y Y Y N/A N Y Y Y
Wood et al. (2015; study 3) Y Y N Y Y Y N Y N/A N Y Y Y
Y = desirable study characteristic present; N = desirable characteristic not present. (A) Is the study design (or
paradigm) described? (B) Detailed inclusion and exclusion criteria provided? (C) Procedures for randomisation
described? (D) Procedures for blinding (if appropriate, i.e. if outcome is experimenter rated) described? (E)
Primary outcome(s) clearly specified? (F) Relevant demographics for subjects provided? (G) Sufficient experi-
mental control (i.e. both a no retrieval + treatment and a retrieval + placebo group included)? (H) Groups
comparable at baseline? (I) Inter-rater reliability achieved and evaluated where relevant? (J) Duration of retrieval
trial provided (or reference made to duration from previous published studies)? (K) Treatment ‘dose’ provided?
(L) Timing of drug administration relative to reconsolidation clearly described? (M)Where relevant, missing data
(> 20%) dealt with appropriately?
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Pharmacological and behavioural reconsolidation
interference procedures
Pharmacological studies most commonly used propranolol
[k = 2 substance use studies (Pachas et al. 2015; Saladin et
al. 2013) and k = 2 phobia/trauma studies (Brunet et al.
2018; Soeter and Kindt 2015a)]. The reconsolidation-
interfering effects of mifepristone (k = 2; Wood et al. 2015;
studies 2 and 3) and sirolimus (rapamycin; k = 1; Surís et al.
2013) on threat memory and memantine (k = 1; Das et al.
2015a) and nitrous oxide (k = 1; Das et al. 2018a) on reward
memory were also examined. In all cases, selection of these
drugs by study authors was based on their putative down-
stream protein synthesis-inhibiting effects and, particularly,
their tendency to interfere with the protein synthesis-
dependent restabilisation phase of reconsolidation.
Among behavioural studies, retrieval-extinction was the
most commonly tested procedure, either using ‘standard’ in
vivo and/or picture-stimulus exposure in specific phobia
(Bjorkstrand et al. 2017; Telch et al. 2017) and substance
use (Germeroth et al. 2017; Xue et al. 2012) or virtual reality
exposure for specific phobia (Maples-Keller et al. 2017;
Shiban et al. 2015). The remaining behavioural studies exam-
ined post-retrieval counterconditioning (Das et al. 2015b) and
cognitive reappraisal (Hon et al. 2016) in substance users
(heavy alcohol drinkers) or prose interference (Kredlow and
Otto 2015) in sub-clinical, trauma-exposed individuals.
Study outcomes
Across all studies, 15 of the 18 ESs were positive (favouring
retrieval-dependent reconsolidation interference).With the ex-
ception of Brunet et al. (2018), who reported high levels of
attrition at 6-month follow-up, ESs are based on comparisons
between the retrieval and control condition on the last
assessed time point for the relevant outcome (the ES for the
study of Brunet et al. (2018) was based on the penultimate
follow-up). For the outcomes selected for the current meta-
analysis, this ranged from 1 day (Shiban et al. 2015) to
12 months (Maples-Keller et al. 2017; Soeter and Kindt
2015a). We deemed this relatively stringent longest time point
comparison to be appropriate given the claim for permanent
memory modification following reconsolidation interference.
Among the phobia/trauma studies, other than outcomes
from the BAT (phobia studies) and trauma symptom
severity/trauma memory recall (trauma-related studies) used
to calculate ESs, some of the reviewed publications reported
additional outcomes showing significant retrieval-dependent
benefits (Table 1). These included reduced skin conductance
in response to fear-provoking stimuli (Maples-Keller et
al. 2017), subjective fear/phobic symptoms (Soeter and
Kindt 2015a) and neural activity in the amygdala
(Bjorkstrand et al. 2016, 2017). Notably, reductions in
subjective fear (of spiders) in the study of Soeter and
Kindt (2015a) only emerged at long-term follow-up, sug-
gesting a lagged benefit for some outcomes following
reconsolidation interference treatments. Conversely,
Maples-Keller et al. (2017) reported relatively higher
physiological arousal (heart rate) at a 3-month follow-
up in the retrieval + treatment (exposure) group, in the
absence of, as well as during, exposure to feared cues.
However, this was interpreted as a relative benefit to the
retrieval group (i.e. high levels of fear were thought to
attenuate physiological reactivity in the no retrieval
group, although there were no between-groups differ-
ences in fear ratings at this time point).
In addition to craving, other statistically significant effects
were also reported in a number of the substance use studies
(Table 1). These included reductions in smoking (Germeroth et
al. 2017), alcohol attentional bias (Das et al. 2015b), alcohol cue
liking (Das et al. 2015b), fluency for positively valenced alcohol
words (Hon et al. 2016) and cocaine and heroin cue-evoked
blood pressure changes (Saladin et al. 2013; Xue et al. 2012).
Control conditions
A control group that received treatment in the absence of
putative reactivation (no retrieval + treatment) was considered
the most appropriate comparison condition and was the most
commonly employed. A number of pharmacological studies
used a retrieval + no treatment (placebo) group (Brunet et al.
2018; Pachas et al. 2015; Saladin et al. 2013; Surís et al. 2013;
Wood et al. 2015; study 3), as did Kredlow and Otto (2015),
who compared negatively valenced interfering prose with a no
prose condition.
Effect size for symptoms of phobia and trauma
The aggregate ES for phobia/trauma symptoms was medium
(k = 10; n = 402; g = 0.44, 95% CI [0.13, 0.74], p = 0.005;
Fig. 2) and showed moderate heterogeneity (I2 = 55%). It is
clear from inspection of the forest plots, however, that the
study of Soeter and Kindt (2015a) contributes disproportion-
ately to the overall ES. A sensitivity analysis showed that
exclusion of Soeter and Kindt (2015a) eliminated heterogene-
ity (I2 = 0%) but also reduced the ES (g = 0.33, 95% CI [0.12,
0.53]), although it remained significantly > 0 (p = 0.002).
The aggregate ES for all pharmacological studies was me-
dium (k = 5, g = 0.59, 95% CI [0.07, 1.11], p = 0.03), and het-
erogeneity was relatively high (I2 = 67%). When Soeter and
Kindt (2015a) was retained in the analysis, the population ES
estimate had poor precision, with the true effect lying in the
range from very small to large-very large (Fig 3a). Exclusion
of Soeter and Kindt (2015a) eliminated heterogeneity (I2 =
0%) but also reduced the ES, although it remained significant
(k = 4, g = 0.32, 95% CI [0.01, 0.62], p = 0.04). A small, non-
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significant ES was found for behavioural studies of phobia/
trauma (k = 5, g = 0.32, 95% CI [− 0.07, 0.70], p = 0.10), with
a moderate degree of heterogeneity (I2 = 46%). Sub-group
analysis showed that pharmacological and behavioural studies
did not significantly differ, regardless of the inclusion
(χ2(1) = 0.69, p = 0.40) or exclusion (χ2(1) = 0.00, p = 1.00)
of Soeter and Kindt (2015a).
Effect size for symptoms related to substance use
Across all substance use studies (Fig. 3b), the aggregate ESwas
small and non-significant (k = 8; n = 372; g = 0.30, 95% CI [−
0.07, 0.67], p = 0.11; Fig. 2), with relatively high levels of het-
erogeneity (I2 = 67%). Sensitivity analysis identified a single
study (Pachas et al. 2015) that appeared to be especially influ-
ential. Its removal reduced heterogeneity to I2 = 24% and in-
creased the aggregate ES to a significant, small-moderate mag-
nitude (k = 7; n = 318; g = 0.44, 95%CI [0.18, 0.70], p < 0.001).
Sub-group analysis of substance use studies indicated that
pharmacological studies (including Pachas et al. 2015) were
associated with a negligible ES (k = 4; n = 184; g = − 0.03,
95% CI [− 0.55, 0.48], p = 0.91) and moderately high hetero-
geneity (I2 = 67%). The three pharmacological studies other
than Pachas et al. (2015) had a small combined ES, which was
non-significant (g = 0.21, 95% CI [− 0.14, 0.56], p = 0.23). In
contrast, behavioural studies yielded a significant, medium ES
(k = 4; n = 188; g = 0.60, 95% CI [0.29, 0.92], p < 0.001), with
low heterogeneity (I2 = 11%). A moderator analysis including
Pachas et al. (2015) suggested that the ESs of behavioural and
pharmacological studies of substance use were significantly
different (χ2(1) = 4.20, p = 0.04; Fig. 3), although removal of
this statistically influential study brought the two effect sizes
closer together such that moderation by treatment was no lon-
ger significant (χ2(1) = 2.63, p = 0.11).
Moderation
Across all studies, meta-regression suggested that none of the
specified moderators (age, proportion of male participants or
methodological appraisal score) were significant predictors of
ES (t values < 1.5, p values > 0.1).
Publication bias
A funnel plot for the phobia/trauma studies did not indicate
asymmetry (t(8) = 0.22, p = 0.831; Fig. 4). No adjustments to
the effect of phobia/trauma studies was suggested by trim and
fill (Duval and Tweedie 2000a, b). The funnel plot for studies
of substance use similarly indicated a lack of asymmetry
(t(6) = 0.956, p = 0.367; Fig. 5), with trim and fill, suggesting
one study with a negative ES was absent. No adjustment to
effect was observed following the exclusion of Pachas et al.
(2015). Overall, these results suggest an absence of publica-
tion bias for phobia/trauma and substance use studies.
Fig. 2 Forest plot of all included studies and a comparison of overall ES for phobia/trauma and substance use studies
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Discussion
This meta-analysis provides a synthesis and critical evaluation
of research on reconsolidation of naturalistic maladaptive
memories using pharmacological and behavioural memory-
weakening/interfering strategies in (sub) clinical samples.
Extension of non-human and human experimental findings
to clinically relevant populations is a relatively new area of
translational research, with the oldest publication in this re-
view dated 2012. As such, there are currently a small number
of relevant studies, although findings across these were rela-
tively consistent. In particular, 15 of 18 ESs were in the pre-
dicted direction (i.e. favouring a reconsolidation-modulation
interpretation), but of the two broad disorder categories, only
the population ES estimate for phobia/trauma (across behav-
ioural and pharmacological studies) was significant.
Fig. 3 a Comparative forest plot for treatment type (behavioural vs. pharmacological) in studies of maladaptive threat memories (phobia/trauma). b
Comparative forest plot for treatment type (behavioural vs. pharmacological) in studies of reward memories (substance use)
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Moderator analysis by intervention type (pharmacological
versus behavioural) indicated statistically larger effects in be-
havioural versus pharmacological studies in the case of sub-
stance use, while the opposite pattern was observed for
phobia/trauma studies, with pharmacological treatments pro-
ducing an almost twofold larger ES than behavioural treat-
ments (although this comparison was not statistically signifi-
cant). However, these general findings need to be considered
in the context of the finding that the ES for each ‘disorder
type’ was substantially influenced by a single study that in-
flated heterogeneity and skewed the results towards either a
larger (phobia/trauma) or smaller (substance use) ES.
General overview of studies
Across all substance use studies, the overall ES was small and
non-significant, although removal of Pachas et al. (2015) re-
duced heterogeneity and increased the aggregate ES estimate,
rendering it significant. Phobia/trauma studies had a signifi-
cant, medium ES when all studies were considered, and a
significant, small-medium ES when Soeter and Kindt
(2015a) was excluded. Overall, these findings support the idea
that, despite their chronological age and strength relative to
experimentally acquired memories, naturalistic maladaptive
memories are capable of being destabilised and subsequently
weakened/overwritten using reconsolidation-modulating
strategies. As such, the putative boundary conditions (memory
remoteness and strength) that appear to limit the
‘destabilisation potential’ of experimentally trained memories
in non-human animals (Milekic and Alberini 2002; Suzuki et
al. 2004; Vousden and Milton 2017) do not necessarily pre-
clude destabilisation of naturally acquired memories in
humans, although they might constrain the degree of
destabilisation and, hence, the magnitude of intervention ef-
fects. This provisional conclusion is promising for the devel-
opment of such strategies as therapeutic interventions for
threat-related and substance use disorders.
However, ESs varied considerably across substance use
and phobia/trauma studies. This might have reflected the sub-
stantial variation in retrieval procedures (e.g. retrieval dura-
tion; timing of treatment relative to retrieval, number of treat-
ment sessions), the nature of reconsolidation interference
strategies (i.e. the use of different drug classes and behavioural
interventions) and participant characteristics. As such, there
continues to be uncertainty about optimal retrieval parameters
and/or retrieval-dependent interference strategies required to
interfere effectively with naturalistic maladaptive memories.
Such memories are likely to constitute highly distributed
traces, involve multiple memory systems (semantic, autobio-
graphical-episodic, priming/implicit; varying in affective va-
lence) and vary substantially in strength and remoteness from
one individual to another. This is clearly very different to the
situation in studies of laboratory-trained memories, in which
learning across participants is uniform and usually involves a
limited set of stimuli from well-defined categories (e.g. sets of
simple sensory stimuli as CSs) within a single context.
Moreover, effective retrieval (reactivating) cues in laboratory
studies are simply those that were used during training, where-
as the nature of suitable (i.e. optimal) retrieval cues for natu-
ralistic memories is unclear. Given the uncertainty regarding
suitable retrieval conditions for naturalistic memories, as well
as the likelihood that such memories are more strongly
entrained (over a long period) than experimentally acquired
memories, it might be expected that ESs would differ between
experimental and naturalist memories. It is therefore instruc-
tive to compare our ES estimates with those obtained in
Fig. 4 Funnel plot of ES against the standard error for studies of phobia/
trauma
Fig. 5 Funnel plot of ES against the standard error for studies of
substance use
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previous meta-analyses of reconsolidation studies of experi-
mentally acquired memories in humans. The results reported
in two relevant meta-analyses on emotional (threat-related)
memories are therefore considered (Kredlow et al. 2016;
Lonergan et al. 2013) in relation to phobia/trauma studies.
Phobia/trauma studies
Kredlow et al. (2016) examined changes in conditioned fear in
studies employing the prototypical behavioural reconsolidation
procedure, retrieval-extinction (Monfils et al. 2009). Their re-
ported aggregate ES, relating to tests of return of fear, is not
dissimilar to that for behavioural strategies (also most
commonly, retrieval-extinction) employed in the phobia/
trauma studies reviewed here. By contrast, the aggregate ES
reported here for phobia/trauma studies using pharmacological
treatments (propranolol, mifepristone and sirolimus; g = 0.71)
was somewhat larger than that reported in a meta-analysis of
studies of the effects of propranolol on memory for negatively
valenced words and cue-induced fear responding (g = 0.56;
Lonergan et al. 2013). Heterogeneity of ESs was broadly sim-
ilar between the currently reviewed behavioural studies and
those in Kredlow et al. (2016) and between the current pharma-
cological studies and those in Lonergan et al. (2013). These
broad similarities underscore the potential for applying research
findings on experimentally acquired memories to naturalistic
memories in clinical disorders. However, they also highlight
the need for further research to identify common sources of
heterogeneity in ESs in reconsolidation research.
As noted above, a single influential study (Soeter and Kindt
2015a) contributed disproportionately to the medium ES of
pharmacological studies summarised here. Removal of this
study substantially reduced the ES. However, given that this
study produced the most pronounced, prolonged (1 year) and
generalised (across behavioural and subjective-evaluative in-
dices of fear memory) effects, it is worth considering the study
features that might have contributed to these particularly large
and durable effects. It is noteworthy, for example, that Soeter
and Kindt (2015a) used post-retrieval propranolol as a phar-
macological interference strategy, and it was also the only
pharmacological study on specific phobia rather than PTSD.
The use of propranolol by these authors was based on their
multiple previous demonstrations of reconsolidation
impairing effects of propranolol on experimentally acquired
memories (conditioned fear; Kindt et al. 2009; Sevenster et al.
2012, 2013, 2014; Soeter and Kindt 2010, 2011, 2012a, b,
2015a; but see Bos et al. 2014; Schroyens et al. 2017). The
use of post-retrieval propranolol may be particularly relevant
to the large effects seen in this study. While specific NMDAR
sub-units have repeatedly been shown to be involved in
destabilisation (see below), the role of β-adrenergic signalling
in this first phase of reconsolidation has been unclear.
However, there is some recent indirect support for the idea
that adrenoceptors might also be involved in destabilisation
and that their premature blockade might therefore constrain
reconsolidation interference effects (Lim et al. 2018). If this is
true, post-retrieval, rather than pre-retrieval propranolol ad-
ministration is likely the optimal strategy for reconsolidation
interference-based therapies.
While fear conditioning reconsolidation studies that have
used propranolol have demonstrated that relatively brief (<
10-s) retrievals involving unreinforced presentation of a CS
appear sufficient to reactivate conditioned fear memories,
Soeter and Kindt (2015a) used a longer retrieval duration
(2 min), as is apparently required for reactivation of chrono-
logically remote memories (Suzuki et al. 2004). This was
substantially longer than the retrievals used in the other
(behavioural) phobia studies reviewed here (Bjorkstrand et
al. 2016; Maples-Keller et al. 2017; Shiban et al. 2015;
Telch et al. 2017). Soeter and Kindt’s (2015a) retrieval proce-
dure also involved a prediction error (spider phobic partici-
pants expected that they would touch a spider during retrieval,
but in fact, this did not occur). Finally, the retrieval procedure
involved in vivo exposure to a spider (cf. Bjorkstrand et al.
2016; Maples-Keller et al. 2017; Shiban et al. 2015), which, as
a biologically ‘prepared’ stimulus, might be considered to
possess qualities of a US. Some researchers (e.g. Liu et al.
2014) have suggested that the use of USs at retrieval results
in a more generalised destabilisation of relevant associations
(between all CSs and the US). This might also explain the
more generalised effects on fear responding observed in
Soeter and Kindt (2015a). A close replication is now required
to establish that this combination of factors (i.e. use of post-
retrieval propranolol, medium duration retrieval and/or use of
cues with US properties and/or incorporating a relevant pre-
diction error at retrieval) reliably produces large and durable
reconsolidation effects on naturalistic fear memories.
Thereafter, studies might seek to determine if this combination
is required.
The basic behavioural pharmacology of other
neurotransmitter/neuromodulator systems in reconsolidation
is less developed relative to the noradrenergic system. For
example, despite the established role of glucocorticoid stress
system in memory, disruption of which is implicated in psy-
chological disorders (de Quervain et al. 2016), few experi-
mental studies have been conducted on the role of this system
in reconsolidation in humans. Moreover, endogenous and ex-
ogenous corticosteroids have a variety of distinct and oppos-
ing effects on memory (e.g. impairment of retrieval versus
enhancement of (re)consolidation), depending upon, for ex-
ample, the timing of the glucocorticoid surge relative to re-
trieval, the number (or duration) of CS exposure at retrieval
(e.g. Cai et al. 2006) and background levels of arousal (see
Meir Drexler and Wolf 2017). These multiple determinants of
glucocorticoid effects might explain the conflicting results
reported in existing human and non-human animal studies of
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glucocorticoid modulation of reconsolidation (de Quervain et
al. 2016). It is unclear whether these considerations were rel-
evant to the two studies ofWood et al. (2015; studies 2 and 3),
both of which showed no statistical effect of mifepristone, a
glucocorticoid receptor antagonist (although effects were in
the predicted direction). In Wood et al. (2015; study 3), the
authors additionally attempted to augment the impairing ef-
fects of mifepristone through pre-treatment with the NMDAR
(glycine site) partial agonist, D-cycloserine. This strategy
might be particularly relevant when long-term allostatic pro-
cesses (Espejo et al. 2016) result in an enduring downregula-
tion of NMDAR (NR2B) sub-units, which are required for
memory destabilisation (Ben Mamou et al. 2006; Wang et
al. 2009). As is evident from Figs. 2 and 3a, DCS did not
appear to affect mifepristone’s ability to interfere with
reconsolidation of trauma memory.
The limited effects of mifepristone might be attributable to
specific procedural factors in the two studies described in
Wood et al. (2015). For example, the use of individualised
scripts likely introduced variability in retrieval duration across
participants. In addition, apparently prolonged ‘script prepa-
ration’ procedures at retrieval (writing about two traumatic
experiences from the same or different events and recalling
subjective, visceral and muscular reactions associated with
these experiences) might have engaged extinction rather than
reconsolidation processes. Alternatively, relatively prolonged
(intermediate) retrieval durations can also engage a so-called
‘limbo state’ (Merlo et al. 2014), in which neither extinction
nor reconsolidation is engaged. These limitations in the extant
research on drugs that downregulate glucocorticoid receptor
activity do not allow firm conclusions to be drawn about their
application as reconsolidation-interfering treatments at this
stage.
Unlike the role of the noradrenergic and glucocorticoid
systems, little is known about the effects of manipulating the
mTOR pathway on any aspect of memory functioning in
humans. While rapamycin blocks fear-related memory
reconsolidation in rodents (e.g. Blundell et al. 2008), this ca-
pacity has not yet been established in experimental studies of
emotional learning and memory in humans. This makes it
difficult to interpret the limited efficacy of rapamycin reported
in Surís et al. (2013). In addition to the long retrieval duration
(up to 75 min) used in that study, the pharmacokinetic profile
of rapamycin (i.e. its central bioavailability after a single
15 mg oral dose) relative to the timing of destabilisation (as-
suming this actually occurred) may not have been optimal.
In contrast to the ES estimate from pharmacological studies
of phobia/trauma, the population ES from studies of post-
retrieval behavioural strategies was small (approximately half
that obtained from pharmacological studies) and not signifi-
cantly different from 0. Despite four of the five ESs favouring
the retrieval + treatment group, the effect was skewed towards
a smaller value by the study of Shiban et al. (2015). The ES in
that study was based on a spontaneous recovery test per-
formed 1 day after retrieval-extinction. If there is a ‘sleeper
effect’ on BAT performance, as found for declarative aspects
of fear by Soeter and Kindt (2015a); note these authors tested
behavioural approach for the first time 11 days after treatment
with propranolol), retrieval-dependent effects might not have
been evident after such a short interval. However, in contrast
to Soeter and Kindt (2015a), Shiban et al. (2015) reported no
evidence for stronger effects of retrieval-extinction on declar-
ative fear after a long follow-up period (6 months). In addition
to differences in the retrieval procedures between these two
studies of spider phobics, (non-significantly) higher baseline
levels of fear, heart rate and skin conductance, as well as lower
baseline approach behaviour in the retrieval-extinction group
(relative to the control group), might have contributed to lim-
ited extinction in the retrieval-extinction group in the study of
Shiban et al. (2015).
One notable finding among the behavioural phobia/trauma
studies was that described by Telch et al. (2017), who reported
a relatively immediate reduction in fear responding (expectan-
cy and peak fear) in the retrieval-followed-by-treatment
(extinction) group relative to the treatment-followed-by-
retrieval control group. These authors consider a number of
explanations for this unexpected early effect (e.g. the occur-
rence of prediction error or increased noradrenergic activity
resulting from the retrieval trial). However, it should also be
noted that the interval between retrieval and the first extinction
trial was especially long in this study (30 min). While the use
of a delay between retrieval and the interference strategy is a
common feature of behavioural reconsolidation studies (al-
though the interval is usually only 10 min), the rationale for
employing such a delay is unclear and may simply be a car-
ryover from the procedure used in the first studies of retrieval-
extinction in rodents and humans (Monfils et al. 2009; Schiller
et al. 2010). Indeed, without employing high cognitive load
tasks between the end of retrieval and the start of the interfer-
ence task (e.g. Das et al., 2015b, 2018b; Hon et al. 2016), there
is the potential for ongoing cognitive engagement/rehearsal
following exposure to the reminder cue, possibly initiating
extinction. This might therefore be an alternative explanation
for the apparent early retrieval-dependent enhancement of ex-
tinction reported by Telch et al. (2017).
Substance use studies
Despite the small number of studies of laboratory-based re-
ward-memory reconsolidation in humans (e.g. Xue et al.
2017; Zhao et al. 2011), there is substantial evidence for
reconsolidation modulation in rodent models of maladaptive
reward/addiction. Meta-analytic findings on appetitive-reward
memory in non-human animals suggest that the ES associated
with reconsolidation interference using NMDAR antagonism
is substantially larger than that for β-adrenergic antagonists
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(Das et al. 2013). This might explain the relatively modest and
short-lived effects of propranolol reported by Saladin et al.
(2013). Alternatively, the retrieval procedure in Saladin et al.
(2013) was relatively protracted (2 × 10 min of in vivo and
video cue exposure to cocaine cues), which might have limit-
ed plasticity through activation of extinction or generating a
limbo state. Another study that used propranolol (Pachas et al.
2015) showed a negative ES (the propranolol group showing
higher levels of craving relative to retrieval + no treatment). It
should be noted, however, that the latter study used a script
preparation protocol inspired by the same studies that in-
formed the retrieval procedures of Wood et al. (2015).
Again, while the duration of the retrieval procedure was not
stated in Pachas et al. (2015), it is likely that it was also
prolonged (and likely to vary between participants). As such,
the potential for extinction/limbo state processes is again rel-
evant. In addition, since craving was higher in the retrieval +
treatment group, it is possible that (inadvertent) extinction
consolidation was impaired by propranolol relative to the pla-
cebo group (Cahill et al. 2000).
Excluding Pachas et al. (2015), the remaining three phar-
macological studies (Das et al. 2015b, 2018a; Saladin et al.
2013) showed no evidence of a combined effect consistent
with reconsolidation interference. Based on the larger effects
of NMDAR versus β-adrenergic antagonists on reward mem-
ory reconsolidation (Das et al. 2013), Das et al. (2015a) ex-
amined the NMDAR antagonists, memantine, but found no
evidence for an effect consistent with reconsolidation block-
ade. It is unclear whether the typical therapeutic dose (10 mg)
and route of administration (oral) of memantine is suitable for
blocking reconsolidation in humans. Indeed, memantine has
slow absorption kinetics and relatively low selectivity for the
most abundant central NR2A NMDAR sub-unit (Ogden and
Traynelis 2011), which is involved in restabilisation (Milton
2013), giving rise to uncertainty about whether suitable reduc-
tions in NMDAR activity were actually achieved in the post-
retrieval period. The other putative NMDAR antagonist used
in this group of studies, nitrous oxide (Das et al. 2018a), also
did not show a reconsolidation blocking effect based on the
planned statistical analysis. However, when the data was
reanalysed to take account of whether participants in the re-
trieval groups experienced a prediction error at retrieval, sig-
nificant retrieval-dependent effects of nitrous oxide were evi-
dent. Since the latter findings were not based on a pre-
specified statistical analysis plan, the ES from this study used
in the current meta-analysis, was based on the non-significant
findings.
In contrast to pharmacological strategies, behavioural
methods for interfering with reconsolidation showed more
promise in the case of substance use. Indeed, the ES associat-
ed with behavioural studies was significantly larger than that
of pharmacological studies, although this statistical finding
needs to be treated with caution, given the small number of
studies and lack of precision in the population ES estimate of
pharmacological studies. Of the four behavioural substance
use studies, two employed post-retrieval cue exposure (re-
trieval-extinction; Germeroth et al. 2017; Xue et al. 2012):
one counterconditioning (Das et al. 2015b) and one cognitive
reappraisal (Hon et al. 2016). All showed positive ESs on
measures of craving, and the overall ES was moderate-large,
with minimal heterogeneity. It is noteworthy that while the
nature of the reactivating cues varied between studies (e.g.
drug use video, in vivo drug cues, drug pictures or a combi-
nation of these), all used the same retrieval duration (5 min),
along with a 10-min interval between termination of retrieval
and start of the behavioural strategy. As such, these retrieval
parameters can be recommended for future substance use
reconsolidation studies, at least until optimal parameters are
firmly established through studies that parametrically vary
retrieval parameters.
In addition, it is noteworthy that all of the substance use
behavioural interference studies reported significant effects on
more than one outcome. Indeed, Das et al. (2015b) reported
results consistent with a comprehensive rewriting of affective,
attentional and cognitive aspects of alcohol-related memories
in heavy drinkers. However, the follow-up period for this
study, along with Hon et al. (2016), was relatively short
(1 week), whereas the other two studies tested participants at
1 month (Germeroth et al. 2017) and 6 months (Xue et al.
2012). Three of the studies examined changes in substance
use behaviour (Das et al. 2015a; Germeroth et al. 2017; Hon
et al. 2016), but only one of these showed significant changes
in drug (cigarette) use (Germeroth et al. 2017). The latter
study, along with the study of Xue et al. (2012), used a two-
session treatment protocol (two retrieval + treatment sessions).
As such, despite low levels of heterogeneity in ESs of these
behavioural studies, there was considerable methodological
variation. It remains to be determined whether countercondi-
tioning and cognitive reappraisal result in sustained effects on
craving [and/or in attentional bias and effective responding to
alcohol (Das et al. 2015b) and semantic memory for alcohol
(Hon et al. 2016)] and whether behavioural effects might also
emerge after a longer delay.
Limitations
The effects reported here are based on a relatively small num-
ber of studies in each category of disorder (these were further
reduced in the treatment-type moderator analyses). In addi-
tion, the studies themselves generally had small sample sizes.
Moderation was only examined for a small number of covar-
iates in the current analysis. However, assuming detailed
methodological reporting in future studies, meta-analysis/re-
gression based on a larger number of studies with greater
variability in retrieval variables might prove to be a particu-
larly effective way of establishing the role of retrieval
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parameters (e.g. retrieval duration; use of prediction error at
retrieval) in successful memory reactivation. The alternative
(and preferable) approach would involve a parametric varia-
tion of these retrieval parameters within individual studies,
although this approach would require very large sample sizes
due to the number of potential factors and levels of key re-
trieval variables that would be manipulated.
In contrast to the array of outcomes reported in the
reviewed studies, our analysis focused on a narrow set of
pre-determined outcomes, primarily trauma symptoms in
studies of trauma-exposed individuals, behavioural approach
or subjective fear (based on BAT performance) in phobia stud-
ies and craving in the case of substance use studies. We opted
to base our ES calculations on these outcomes rather than
those reported as statistically significant in publications.
However, it is possible that quite different results would be
achieved if only the significant results reported by study au-
thors (either singly or as composites of multiple significant
outcomes) were used to determine ESs. This is not necessarily
a limitation, as our intention was to reduce the potential for
bias in cases where multiple outcomeswere reported, but none
was pre-specified as primary.
Recommendations for future research
The strength of the reviewed studies was their tendency to
recruit participants in line with the relative gender prevalence
of disorders in question. However, it should be noted that
recent evidence suggests that men and women may be differ-
entially susceptible to some reconsolidation-interfering treat-
ments. In particular, Meir Drexler et al. (2016) showed that
whereas men showed retrieval-dependent weakening follow-
ing hydrocortisone, this effect was absent in women. It is
currently unclear whether this finding is specific to glucocor-
ticoid modulation of reconsolidation, rather than reflecting a
general insensitivity to reconsolidation interference in women.
Indeed, the latter seems highly unlikely, given the very large
effects seen with propranolol in Soeter and Kindt (2015a),
whose sample consisted almost exclusively of women
(91%). No individual study that we are aware of has yet ex-
amined gender moderation in (sub) clinical populations, al-
though this seems a particularly important factor to consider
if reconsolidation interference is to be used clinically. It should
be noted provisionally that our moderation analysis did not
suggest an effect of gender.
Among the pharmacological studies, there was no common
use of a single reconsolidation-interfering drug. Although pro-
pranolol was most commonly studied, this amounted to only
two studies in the substance use category and two studies in the
phobia/trauma grouping. As such, it remains unclear whether
one drug class category might be more effective in preventing
restabilisation than others. Despite strong evidence from studies
with non-human animals, only two of the reviewed studies
examined an NMDAR antagonist. Given the central role of
glutamatergic neurotransmission in learning and memory, fur-
ther research on the effects of NMDAR antagonist effects on
reconsolidation in humans seems to be a special priority. On the
other hand, clinical studies should be preceded by more basic
psychopharmacological studies in order to determine the im-
portance of drug timing (relative to retrieval) and route of ad-
ministration. This is particularly important given the potential
for iatrogenic effects of NMDAR antagonists (i.e. the potential
for paradoxical strengthening of maladaptive memories in
some contexts (Honsberger et al. 2015)).
Despite its reported importance in memory destabilisation,
a minority of the reviewed studies examined the role of pre-
diction error (cf. Das et al. 2015a, b, 2018a; Hon et al. 2016;
Soeter and Kindt 2015a). As noted previously, if there is a
requirement for an optimal learning signal at retrieval, those
studies showing beneficial effects of retrieval + treatment in
the absence of prediction error might, in fact, represent the
lower bound of efficacy that could be achieved during
reconsolidation modulation. As such, tailoring retrieval pro-
cedures to maximise PE may bolster the likelihood that
reconsolidation can be leveraged for clinical benefit.
Overall, our findings suggest that reconsolidation interfer-
ence is worth pursuing as a clinical strategy. However, before
proceeding with costly and labour-intensive clinical trials, the
multiple sources of uncertainty regarding determinants of ef-
ficacy of this approach should be more thoroughly investigat-
ed through basic experimental human and animal research to
ensure that studies with clinical populations are optimised
and, therefore, as informative as possible.
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